Zobrazeno 1 - 10
of 919
pro vyhledávání: ''
Publikováno v:
Leuk Lymphoma
Relapsed/refractory Primary Central Nervous System Lymphoma (R/R PCNSL) has a poor prognosis with no established preferred treatment. We report the efficacy and toxicity of a combination chemotherapy regimen: methotrexate, carmustine, etoposide, and
Autor:
Boris Kollárik, Michal Mego, Zuzana Sycova-Mila, Jozef Mardiak, Jan Slopovsky, Katarina Rejlekova, Michal Chovanec, Patrik Palacka, Jana Obertova
Publikováno v:
Anticancer Research. 41:5749-5759
BACKGROUND/AIM Systemic immune-inflammation index (SII) predicts survival of patients with various malignancies. This study explored the prognostic value of SII in metastatic urothelial carcinoma (MUC) subjects. PATIENTS AND METHODS We evaluated 181
Autor:
Shogo Teraoka, Atsushi Takenaka, Katsuya Hikita, Masashi Honda, Hideto Iwamoto, Shuichi Morizane, Bunya Kawamoto, Noriya Yamaguchi, Tetsuya Yumioka, Ryutaro Shimizu
Publikováno v:
Anticancer Research. 41:5767-5773
BACKGROUND This study aimed to investigate the response to platinum-based chemotherapy rechallenge in patients with pembrolizumab-refractory urothelial carcinoma. PATIENTS AND METHODS We retrospectively reviewed 14 patients with pembrolizumab-refract
Publikováno v:
Anticancer Research. 41:5729-5737
Background/aim This study aimed to identify the predictive markers for carboplatin-induced severe thrombocytopenia. Patients and methods We conducted a retrospective cohort analysis of inpatients who received carboplatin and pemetrexed. Results Among
Autor:
Xiaoyong Huang, Zhiqiang Wu, Wenbo Guo, Zhiyong Liu, Tengfei Li, Xu Bo, Weiguang Yu, Song Chen, Yanqing Wu, Pengfei Wang
Publikováno v:
BMC Cancer, Vol 21, Iss 1, Pp 1-13 (2021)
BMC Cancer
BMC Cancer
Background Not all patients with unresectable hepatocellular carcinoma (uHCC) benefit from treatment with immune checkpoint inhibitors and molecular-targeted agents. The aim of this retrospective study was to assess the efficacy and safety of pembrol
Autor:
Jean El Cheikh, Iman Abou Dalle, Jeries Kort, Farouk Al Chami, Maya Charafeddine, Haidar El Darsa, Rola El Sayed, Ali Ibrahim, Ali Bazarbachi
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 21:711-719
Background Intensified immunochemotherapy with rituximab, doxorubicin, cyclophosphamide, vindesine, bleomycin, and prednisone (R-ACVBP) improves outcomes in younger adults with diffuse large B-cell lymphomas (DLBCL) compared with R-CHOP. Due to vinde
Autor:
Hiroshi Uchi, Satoshi Fukushima, Yuki Yamamoto, Shigeto Matsushita, Hiroshi Kato, Yasuhiro Fujisawa, Ryo Amagai, Takeo Maekawa, Kentaro Ohuchi, Yusuke Muto, Yumi Kambayashi, Koji Yoshino, Taku Fujimura
Publikováno v:
Melanoma Research. 31:575-578
Patients with resected stage IIIB, IIIC and IIID melanomas have a high risk of recurrence. Therefore, an appropriate protocol for stage III melanoma is needed. Since adjuvant dabrafenib plus trametinib (D+T) combined therapy and anti-PD1 antibody (Ab
Publikováno v:
Anti-Cancer Drugs. 33:e534-e540
We aimed to assess the prognostic and predictive significance of pretreatment Prognostic Nutritional Index (PNI) in extensive-stage small-cell lung cancer (ES-SCLC) patients treated with first-line chemotherapy. We designed this study to evaluate the
Autor:
Gina Klee, Patrick Terheyden, Jonas K. Kurzhals, Victoria Hagelstein, Detlef Zillikens, Ewan A. Langan, Andreas Recke
Publikováno v:
Melanoma Research. 31:464-471
Combined immunotherapy is associated with a significant risk of severe and potentially fatal immune-related adverse events (irAEs). Therefore, we retrospectively analyzed the side profile and efficacy of low-dose ipilimumab (1 mg/kg, IPI1) combined w
Autor:
Cristiana Sessa, Monia Guidi, Laura Moser, Eleftherios P. Samartzis, Mariarosa Pascale, Ilaria Colombo, Tatiana Terrot, Milo Frattini, Simone Brandt, Anastasios Stathis, Sheila Gaggetta, Sofia Genta, Federica Martorana
Publikováno v:
Clinical Cancer Research. 27:5012-5019
Purpose: This phase I study evaluated safety, tolerability, pharmacokinetics, and preliminary activity of the PI3K/mTORC1/2 dual inhibitor gedatolisib combined with carboplatin and paclitaxel. Patients and Methods: Patients with advanced solid tumors